Alliqua (ALQA) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Alliqua BioMedical, Inc. Reports Second Quarter Financial Results
August 6, 2015 7:05 AM EDTLANGHORNE, Pa., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq: ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced financial results for the second quarter ended June 30, 2015.
Q2 Highlights:
Total revenue increased 202% year-over-year to $3.1 million. Organic revenue growth was approximately 99% year-over-year. Products revenue increased 383% year-over-year to $2.7 million, of which organic product revenue growth was 188% year-over-year. Gross margin was 56.2% compared to 19.3% last year and 42.9% in the first quarter of 2015. On April 16th, Alliqua announced that the Company's Biovance® Human Amniotic Membrane Allograft received... MoreAlliqua BioMedical, Inc. Reports Second Quarter Financial Results
August 6, 2015 7:05 AM EDTLANGHORNE, Pa., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq: ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced financial results for the second quarter ended June 30, 2015.
Q2 Highlights:
Total revenue increased 202% year-over-year to $3.1 million. Organic revenue growth was approximately 99% year-over-year. Products revenue increased 383% year-over-year to $2.7 million, of which organic product revenue growth was 188% year-over-year. Gross margin was 56.2% compared to 19.3% last year and 42.9% in the first quarter of 2015. On April 16th, Alliqua announced that the Company's Biovance® Human Amniotic Membrane Allograft received... More